Cardiology meeting highlights 2022: Results of SPORT, DELIVER trials and more

Healio and Cardiology Today have curated a list of the top cardiology and cardiac/vascular intervention news reported from meetings in 2022.

Readers were most interested in the superiority of statins over dietary supplements for cholesterol lowering; updates in HF treatment and clinical guidelines; use of cerebral embolic protection during transcatheter aortic valve replacement; and more.

Statin therapy ‘vastly superior’ to common dietary supplements for cholesterol lowering

Daily rosuvastatin lowered LDL, total cholesterol and serum triglycerides significantly more than placebo and six common over-the-counter dietary supplements, with no supplement lowering LDL more than placebo. Read more

Dapagliflozin ‘foundational therapy’ for HF, regardless of EF: DELIVER

In adults with HF with mildly reduced or preserved ejection fraction, dapagliflozin significantly reduced risk for CV death and worsening HF compared with placebo, with no attenuation of treatment benefit for patients with the highest EF. Read more

Precision testing strategy strongly benefits stable patients with suspected CAD

In stable symptomatic patients with suspected CAD, a precision testing strategy was linked to a 70% reduction in death, MI or catheterization without obstructive CAD at 1 year compared with the usual testing. Read more

VALOR-HCM: Mavacamten reduces need for septal reduction therapy in obstructive HCM

The cardiac myosin inhibitor mavacamten, compared with placebo, reduced the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy. Read more

Treating mild chronic hypertension in pregnancy appears beneficial, safe for mother and baby

Treating mild chronic hypertension during pregnancy to a BP goal of less than 140/90 mm Hg reduced adverse pregnancy outcomes and did not impair fetal growth. Read more

Updated guideline redefines HF stages, emphasizes prevention, new treatments

A joint guideline from the American College of Cardiology, the American Heart Association and the Heart Failure Society of America redefines HF stages to focus on prevention and recommends HF treatment with SGLT2 inhibitors. Read more

Polypill soon after heart attack lowers risk for major adverse CV events: SECURE

In older adults, a polypill containing aspirin, an ACE inhibitor and a statin within 6 months after myocardial infarction lowered the risk for major adverse CV events compared with usual care. Read more

Cerebral embolic protection during TAVR did not reduce overall stroke

In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, cerebral embolic protection did not decrease incidence of periprocedural stroke. Read more

Pascal noninferior to MitraClip for treatment of degenerative mitral regurgitation

A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in a head-to-head trial in patients with severe symptomatic degenerative mitral regurgitation. Read more

Consequences of open artery ischemia underappreciated

The medical community needs to understand that uncontrolled open artery ischemia is not benign, a speaker stated. Read more